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ABSTRACT
The thyroid transcription factor (TTF)-1 has an essential role in
lung morphogenesis and development. It is involved in the transcrip-
tion of surfactant proteins (SP), which are critical in respiratory
function. Neonates with congenital diaphragmatic hernia die of re-
spiratory failure caused by pulmonary hypoplasia with associated
biochemical immaturity. To gain new insights into the causes of this
disorder and the effect of prenatal hormonal treatment on reducing
mortality in these infants, we evaluated the expression of TTF-1 as
marker of lung morphogenesis and SP-B as marker of lung maturity.
Using a rat model of lung immaturity, we show that TTF-1 and SP-B
messenger RNA (mRNA) levels are drastically reduced in congenital
lung hypoplasia. Interestingly, prenatal dexamethasone (Dex) treat-
ment increased both TTF-1 and SP-B mRNAs over control levels when
administered to rats with lung hypoplasia, but it had no effect on
TTF-1 or a moderate effect on SP-B mRNA when administered to
control rats. TRH alone also increases TTF-1 and SP-B mRNA levels
but to a lesser extent than Dex. When administered together with
Dex, TRH counteracts the induction observed with the glucocorticoid.
The decrease in TTF-1 mRNA levels in lung hypoplasia is paralleled
by a down-regulation of TTF-1 protein levels, as well as by a decrease
in the TTF-1/DNA complex when the TTF-1-binding site of the SP-B
promoter was used as a probe. Both parameters were reestablished
after glucocorticoid treatment. Moreover, the regulation of TTF-1
gene expression described in this report is accompanied by the same
regulation in its promoter activity, as demonstrated in transfection
experiments performed in H-441 human lung-derived adenocarci-
noma cells. In conclusion, our data demonstrate, for the first time,
that lung hypoplasia and the associated respiratory dysfunction
caused by SP-B deficiency are caused, in part, by down-regulation of
TTF-1 gene expression. The observations that prenatal glucocorticoid
treatment induces the expression of TTF-1 supports routine in utero
glucocorticoid treatment of patients expected to have lung hypoplasia.
(Endocrinology 141: 2166–2173, 2000)
LUNG MORPHOGENESIS and development are knownto require the presence of transcription factors (1) that
activate or repress the expression of specific genes. In both
processes, members of the forkhead family, HNF-3a and
HNF-3b (hepatocyte nuclear factors 3 a and b), the home-
odomain proteins Hoxa5 and TTF-1 (thyroid transcription
factor 1), and members of the nuclear receptor superfamily
(including receptors for glucocorticoids, thyroid hormones,
and retinoids) are involved. TTF-1 is a homeodomain-con-
taining transcription factor (2), expressed in two of the many
structures derived from the foregut endoderm, the thyroid,
and the lung (3). TTF-1 messenger RNA (mRNA) is detect-
able within the ventral migrating edge of the lung bud on
embryonic day (E) 9.5 in the rat (3). In E11.5, a strong signal
can be detected in both branches of the primitive bronchi,
and from E13.5–E15.5, TTF-1 mRNA is expressed in the bron-
chial epithelium. In late gestation stages (E17.5), TTF-1 is
present in epithelial cells of the bronchioli. TTF-1 is involved
in the transcription of pulmonary surfactant proteins (SP-A,
SP-B, and SP-C) and clara cell secretory protein (4–7), as well
as in thyroid-specific genes such as thyroglobulin, thyroid
peroxidase, TSH receptor, and Na1/I2 symporter (8–14).
Surfactant protein B (SP-B) is a hydrophobic protein that
enhances the spreading and stability of surfactant phospho-
lipids in the alveolus. Ablation of the SP-B gene in transgenic
mice demonstrates the critical role of SP-B in the initiation of
lung inflation at birth. Homozygous SP-B (2/2) mice died
of respiratory failure immediately after birth (15), and their
lungs, normally developed, remained atelectatic. An essen-
tial role for TTF-1 in lung and thyroid morphogenesis has
been established, because homozygous TTF-1 null mutant
mice show dilated sac-like structures in the pleural cavity
rather than normal lungs (16). These structures had a rudi-
mentary bronchial tree (but no bronchioli, alveoli, or pul-
monary parenchyma) and an abnormal epithelium. This mu-
tant died of respiratory distress immediately after birth and
lacked the thyroid; the hypothalamus was severely affected
(16) and have defects in tracheoesophageal morphogenesis
(17). Other transcription factors are required for normal lung
morphogenesis, such as HNF-3a and HNF-3b, both of which
are expressed in endoderm derivatives during embryogen-
esis and lung development (18, 19) and are involved in
regulation of TTF-1 gene expression (20). The role during
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development of the glucocorticoid receptor (GR) was inves-
tigated by generation of GR-deficient mice (21). GR null mice
show respiratory distress at birth and die within a few hours.
The lungs are severely atelectatic, and development is im-
paired from day 15.5 of gestation. These observations sug-
gest: 1) a possible role for these transcription factors in the
pathogenesis of pulmonary hypoplasia; and 2) prompt re-
search into how their expression is altered in this disorder
during embryogenesis.
Newborns with congenital diaphragmatic hernia, a mal-
formation that occurs in up to 1:2200 births, still have a poor
prognosis, in spite of recent therapeutic progress. This high
mortality rate is attributable mainly to neonatal respiratory
failure caused by the associated severe pulmonary hypopla-
sia, with physiological and biochemical immaturity. Aiming
at better understanding the pathophysiology of pulmonary
hypoplasia, a reproducible animal model was developed in
neonatal rats by feeding nitrofen (NF) (2,4-dichlorophenyl-
p-nitrophenyl ether) to timed-mated pregnant rats in an ap-
propriate embryological window (22). Lung hypoplasia (23)
and immaturity (24), observed in rat fetuses born to exposed
females, are very similar to those found in the human dis-
orders. In this rat model, the most severe pulmonary defects
were observed only after exposure to NF between E9–E11,
and not before this stage (22). Nitrofen is detected in the
embryonic compartment, 3 h after administration, with a
peak, 72 h later, that corresponds to E12–E14 (25). Nitrofen
is thus present in the embryo at the time at which TTF-1 is
expressed in lung. These observations suggest a possible
alteration of TTF-1 in lung hypoplasia. Using the above rat
model, we determined TTF-1 expression as a marker of ad-
equate lung morphogenesis, and SP-B expression as an in-
direct marker of lung maturity. We report here that expres-
sion of TTF-1 is severely decreased in lung hypoplasia.
Glucocorticoids are used clinically to induce lung matu-
ration and surfactant production in human fetuses expected
to be delivered prematurely. This antenatal hormonal ther-
apy is known to accelerate pulmonary development in pre-
mature neonates and has decreased the incidence of respi-
ratory distress syndrome and pulmonary complications of
preterm birth (26, 27), but the mechanism remains unclear.
The addition of TRH therapy is no more beneficial than
glucocorticoids alone (28). We investigated the effect of this
antenatal hormonal therapy on TTF-1 expression. Our results
show that glucocorticoid therapy to animals with lung hy-
poplasia restores the expression of this transcription factor,
supporting routine in utero glucocorticoid treatment for pa-
tients expected to suffer lung hypoplasia.
Materials and Methods
Animals
Sprague Dawley rats, maintained in environmental conditions with
controlled temperature and an artificial dark-light cycle, were used
throughout the study. Animals were fed ad libitum with a standard
laboratory diet. We used animals weighing approximately 250 g. Fe-
males were caged with fertile males overnight, and mating was con-
firmed by the presence of spermatozoa in a vaginal plug (day 0). All
animals were treated according to an experimental protocol approved
by our institutional research committee that ensures that all require-
ments for animal research (EC86/liter609) are followed.
Experimental design
A scheme representing the animal treatment appears in Fig. 1 and was
carried out as follows. After light ether anesthesia, time-mated pregnant
rats received intragastrically, on day 9.5 of gestation, either 100 mg NF
(NF group) (Wako Chemicals, Neuss, Germany) diluted in pure olive oil
(1) or the same volume of vehicle (control group). Dams of both groups
also received different hormonal therapies to accelerate pulmonary de-
velopment. The dexamethasone (Dex) and NF 1 Dex groups received
0.4 mg/kg Dex ip on days 19 and 20. The TRH and NF 1 TRH groups
were implanted ip on day 18 with an osmotic minipump (Alzet, model
2ML2; Alza Corp., Palo Alto, CA) containing 100 mg/kg TRH, after
which 25 mg/kg TRH were ip injected. Other groups of animals were
treated with combined hormonal treatment (Dex 1 TRH and NF 1 Dex
1 TRH groups), receiving Dex and TRH as described for Dex and TRH
groups. To reproduce all manipulations, animals not treated with TRH
had an Alzet minipump containing saline buffer, and animals not treated
with Dex received ip saline buffer. TRH and Dex were purchased from
Sigma (St. Louis, MO). The fetuses were recovered on day 21 by cesarean
section, examined, weighed, and dissected under a binocular operating
microscope for diaphragm inspection and lung recovery. Rat fetuses
were weighed and their lungs immediately frozen for subsequent RNA
and nuclear protein extraction. Fetal lung weight/BW ratio (mg/g) was
significantly smaller (P , 0.05) in NF-treated rats (16.68 6 1.02), com-
pared with control groups (31.33 6 1.15), indicating that NF clearly
produces lung hypoplasia, thus validating our model of study. Dex
reverts the effect of NF on lung hypoplasia (24.05 6 1.95), making its
effect statistically significant (P , 0.05).
Cell culture
The human lung-derived adenocarcinoma cell line H-441 (or NCI-
H441, ATCC HTB 174) was obtained from American Type Culture
Collection (Manassas, VA) and was maintained in RPMI 1640 medium
supplemented with 10% FBS (Life Technologies, Inc., Gaithersburg,
MD). These cells express TTF-1 (29, 30) and pulmonary-specific SPs A
and B (30, 31).
FIG. 1. Experimental design. Adult female Sprague Dawley rats
were mated with fertile males. The gestational ages are indicated by
numbers (vaginal plug positive, day 0; full-term, day 22). Left diag-
onal arrows, Intragastrically fed with NF (NF-treated groups) or with
oil (Control groups). Dams of both groups were subdivided into dif-
ferent groups, according to the subsequent treatment received. The
groups are indicated in the left portion of the figure. Vertical arrows,
ip injection of the hormonal therapies (or the placebo solution) on the
corresponding gestational day; shadow long arrows, infusion with
osmotic minipump from day 18 with TRH or with the placebo solution
(open long arrows); right diagonal arrows, cesarean section performed
1 day before term; Dex 1 TRH, combined hormonal treatment.
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RNA isolation and Northern blot analysis.
Fetal lungs from different groups were pooled separately, and total
RNA was isolated with guanidine isothiocyanate and cesium chloride
centrifugation (32). Total RNA was electrophoresed on a formalde-
hyde-1% agarose gel and transferred to nytran membrane (Schleicher &
Schuell, Inc., Keene, NH). Hybridization was carried out using a 0.6-kb
EcoRI fragment of rat TTF-1 (2) and a 0.5-kb PstI fragment of rat SP-B
(33). All probes were isolated and labeled with [a-32P] deoxycytidine
triphosphate (ICN Biochemicals, Irvine, CA.) by random oligopriming
to a specific activity of 1 3 109 cpm/DNA. Northern blot images were
analyzed quantitatively using a scanning densitometer and image soft-
ware and normalized with the methylene blue-stained 18S ribosomal
RNA.
Transfection assays
Ten micrograms of a luciferase-linked chimeric construct, spanning
2.8 kb of the human TTF-1 59-flanking region subcloned in the reporter
vector pSV0AL-A59 (34), were transiently transfected into H-441 cells
by the calcium phosphate precipitation method (35). The plasmid RSV-
CAT (2 mg) (36) was also transfected and used to normalize transfection
efficiency. After transfection, cells maintained under different condi-
tions were harvested. Luciferase and CAT activities were measured as
described (35, 37). In the experiments indicated, 2 mg of the TTF-1
expression vector (pCMV-THA) (38) or the corresponding empty vector
(pRC-CMV) were cotransfected.
Electrophoretic mobility shift assays
Nuclear extracts from lungs were prepared, following the method of
Gorski et al. (39). Protein concentration was determined with the Bio-Rad
Laboratories, Inc. kit (Bio-Rad Laboratories, Inc., Richmond, CA) and
BSA as standard. Gel shift assays were performed with the TTF-1-
binding site of human SP-B promoter as probe (4). The oligonucleotide
SPB-f1, derived from positions 2113 to 290 of human SP-B promoter,
was labeled with T4 polynucleotide kinase and [g-
32P] ATP (ICN., Irvine,
CA) and annealed as described (40). For binding reactions, 10 mg of
nuclear proteins were preincubated in a binding reaction mixture con-
taining 40 mm HEPES (pH 7.9), 200 mm KCl, 0.5 mm dithiothreitol, 0.2
mm EDTA, 5% Ficoll, and 3 mg poly (dI-dC) for 15 min on ice. In
competition experiments, the unlabeled oligonucleotide was added in
excess (1003). Labeled oligonucleotide was added to the mixture and
incubated for 30 min at room temperature. For supershift assay, 1 ml
anti-TTF-1 antibody (3) was added before the addition of the probe and
was incubated for 3 h. As a control of supershift specificity, a preimmune
serum was used and incubated in the same conditions. The resulting
DNA-protein complexes were separated from free DNA on a 5% poly-
acrylamide gel (29:1, acrylamide-bisacrylamide). Gels were resolved at
20 mA in a cold room in 0.5 3 TBE [1 3 TBE is 90 mm Tris, 90 mm boric
acid, and 1 mm EDTA (pH 8)] before being vacuum dried and exposed
to x-ray film at 270 C.
Immunoblotting analysis
Nuclear protein extracts (40 mg) were separated in SDS-PAGE. Pro-
teins were transferred to nitrocellulose membranes (Schleicher &
Schuell, Inc.), in a buffer containing 25 mm Tris, 200 mm glycine, and 20%
methanol. After blocking the membranes with 10% low-fat dried milk
in Tris-buffered saline containing 0.05% Tween-20, immunodetection
was performed using the antibody anti-TTF-1 (3). After probing with the
antibodies, membranes were incubated with a streptavidin-conjugated
antirabbit-specific secondary antibody. Immunoreactive bands were vi-
sualized using the luminol reagent (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA). To assess specificity and equivalent loading of the
samples, the same blots were reprobed with a specific anticonstitutive
transcription factor anti-CTF/NF-1 antibody (sc-870) (Santa Cruz Bio-
technology, Inc.).
Statistical analysis
Statistical significance between different treatments was determined
using Student’s t test. Differences are considered significant at P , 0.01.
Results
TTF-1 and SP-B gene expression is down-regulated in lung
hypoplasia, and glucocorticoids rescued their expression
over control values
We studied whether TTF-1 gene expression is altered in
lung hypoplasia. To do so, we performed Northern blot
analysis with 30 mg total RNA extracted from control or
hypoplastic lungs of fetuses after NF treatment. TTF-1
mRNA levels are strongly decreased in the hypoplastic lungs
(NF group) (Fig. 2A). The values obtained after quantitation
were 75% lower than the corresponding control (Fig. 2C,
compare Control and NF groups). Based on the extensively
use of Dex as a treatment to induce lung maturation, we next
studied its effect in TTF-1 mRNA levels of control and hy-
poplastic fetal lungs. Pregnant rats, untreated or treated with
FIG. 2. Effect of NF, Dex, and TRH on TTF-1 and SP-B mRNA levels
in rat fetal lungs. Total RNA (30 mg) was extracted from rats’ fetal
lungs, treated under the experimental protocol described in the Fig.
1 legend, then hybridized with the TTF-1 (A) or the SP-B probe (B).
Arrows, mRNA size. The lower panel shows the methylene blue stain-
ing of 18S ribosomal RNA (rRNA) for loading control. C and D, Quan-
titation of TTF-1 and SP-B mRNAs, respectively, after correction with
the 18 S, by densitometer scanning of autoradiograms from three
independent experiments. The TTF-1 and the SP-B mRNA levels,
expressed as arbitrary units, refers to its control (5 1) in each case.
The data are mean 6 SEM of three independent experiments. Signif-
icant differences among groups are indicated, and means. *, P , 0.01
(one group vs. control group); , P , 0.01 (one group vs. NF group);
ø, P , 0.01 (one group vs. NF 1 Dex group).
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NF, received Dex, as described in Materials and Methods. Total
RNA was extracted from fetal lungs, and the TTF-1 mRNA
levels were analyzed by Northern blot. Interestingly, Dex
treatment markedly increased (10-fold) TTF-1 mRNA levels
when it was administered to NF-treated rats (Fig. 2, A and
C, compare NF with NF 1 Dex groups), but it had no sig-
nificant effect on control rats (Fig. 2, A and C, compare
Control with Dex groups). The observation that Dex treat-
ment of hypoplastic lungs not only rescues the TTF-1 mRNA
levels but also increases these levels over control values
(3-fold) (Fig. 2, A and C, compare Control with NF 1 Dex
groups) is very important. It has been suggested that com-
bined antenatal glucocorticoid and TRH treatment result in
synergistic improvement of lung function of premature ne-
onates (41). We studied the role of this combined treatment
in lung hypoplasia. TRH was administered alone or with Dex
to pregnant mothers, untreated or previously treated with
NF, as described in Materials and Methods. The results ob-
tained in Northern blot analysis show that TRH alone in-
creases TTF-1 mRNA levels (5-fold) when given to NF-
treated rats (Fig. 2, A and C, compare NF and NF 1 TRH
groups), but it has no a significant effect when given to
control rats (Fig. 2, A and C, compare Control and TRH
groups). It is important to mention that the increase obtained
with TRH was approximately half of that obtained with Dex
and that, when both hormones were coadministered to NF
rats, TRH decreased by 2-fold the marked effect obtained
with Dex on TTF-1 mRNA levels (Fig. 2, A and C, compare
NF 1 Dex with NF 1 Dex 1 TRH groups). The combined Dex
and TRH treatment did not induce a significative effect on
TTF-1 mRNA levels when administered to control rats (Fig.
2, A and C, compare Control and Dex 1 TRH groups).
Because of the low TTF-1 mRNA levels in hypoplastic
lungs and their reversion over the control values with Dex,
we determined the SP-B mRNA levels. The same Northern
blots were hybridized with the SP-B probe. The results show
a decrease in SP-B mRNA levels in hypoplastic lungs (NF),
when compared with control values (60% lower than con-
trols) (Fig. 2, B and D). The hormone therapy has an action
on the SP-B mRNA levels similar to that obtained for TTF-1
transcript, although some differences have been observed.
Thus, Dex markedly increased SP-B mRNA levels, both in
NF-treated (18-fold) and control (7-fold) rats (Fig. 2, B and D).
TRH, alone or combined with Dex, increased SP-B mRNA
levels more than TTF-1 mRNA levels, although to a lesser
extent than the glucocorticoid alone. The effect was observed
in both NF-treated and untreated (control) rats. It is impor-
tant to comment on two observations: 1) the maximum effect
on SP-B mRNA levels was obtained in hypoplastic lungs
treated with Dex, with increases of 7- to 8-fold over control
values; and 2) the TRH effect counteracts the Dex effect when
administered to hypoplastic lungs. From these data, we con-
clude that TTF-1 and SP-B are strongly decreased in lung
hypoplasia. Furthermore, SP-B is under hormonal regulation
in both normal and hypoplastic lungs, whereas TTF-1 is
regulated only in hypoplastic lungs. These results suggest
that SP-B is regulated by TTF-1-dependent and -independent
mechanisms and that TTF-1-mediated regulation is an im-
portant mechanism of control in lung hypoplasia.
Because Dex treatment induces the maximal effect on
TTF-1 mRNA levels, when administered to rats with hypo-
plastic lungs, we next determined whether this effect is cor-
related with protein levels. We assayed TTF-1 protein, by
immunoblotting analysis, in nuclear protein extracts (Fig. 3)
and found that TTF-1 protein levels are drastically reduced
in hypoplastic lungs (NF), as compared with the control
group. Again, Dex has no effect when administered to con-
trol animals (Dex), but it increased TTF-1 protein levels, over
the control, when administered to NF-treated rats (NF 1
Dex). The effect is specific, as demonstrated by reprobing the
same Western blots with the constitutive CTF/NF-1 tran-
scription factor, also expressed in lungs (42). These results
suggest that lung hypoplasia is caused by down-regulation
of the homeotic transcription factor TTF-1. The possible
mechanism of the therapeutic action of glucocorticoids in
lung hypoplasia, inducing lung maturation and surfactant
production, may be explained, at least in part, by an increase
in TTF-1 gene expression.
The binding activity of nuclear factor TTF-1 to the SP-B
proximal promoter is reduced in hypoplastic lungs and
reestablished after glucocorticoid treatment
SP-B and TTF-1 are under TTF-1 control; thus, we hypoth-
esized that the decreased levels of both mRNAs may reflect
changes in TTF-1 protein bound to DNA. Gel shift assays
were performed with an oligonucleotide derived from the
TTF-1-binding site of the SP-B promoter (SPB-f1 probe) (4)
and with nuclear extracts from control and NF-treated fetal
lungs. The data in Fig. 4 show a retarded protein/DNA
complex in the control groups (lane 2), which is consistently
reduced in NF-treated rats (lane 8). The complex is specific,
as demonstrated in competition experiments with a 100-fold
excess of a related (lane 3) or an unrelated (lane 4) oligonu-
cleotide. We also investigated the effect of hormonal therapy
in the gel shift assay. Dex, TRH, or both hormones together
did not modify the intensity of the DNA complex when
nuclear extracts from control groups were studied (Fig. 4,
compare lane 2 with lanes 5–7). Interestingly, the adminis-
tration of Dex to NF-treated rats showed a marked increase
in the intensity of the complex (Fig. 4, compare lanes 8 and
9), whereas TRH (lane 10) or TRH plus Dex (lane 11) in-
creased it only slightly. Supershift assays were performed to
confirm TTF-1 implication in complex decrease or increase
(Fig. 5). The complex formed with nuclear extract from con-
trol lungs (lane 2) was recognized by a specific a-TTF-1
FIG. 3. TTF-1 protein levels in control and hypoplastic fetal lungs,
untreated or Dex-treated. Representative Western blot was per-
formed with 40 mg of nuclear proteins extracted from fetal lungs of
control and NF groups, untreated or treated with Dex, and probed
with specific anti-TTF-1 antibody. CTF/NF-1 protein was used as the
loading control.
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antibody inducing a clear supershift (lane 5). The protein/
DNA (lane 6) and TTF-1 supershift (lane 8) complexes de-
creased in NF-treated rats; and again, Dex restored both
complexes (lane 9 and 11) over control levels when admin-
istered to hypoplastic lungs. The specificity of the complex
was assayed with the corresponding 100-fold excess of the
related (lanes 3, 7, and 10) and unrelated (lane 4) oligonu-
cleotides. As a control of the supershift assay, the labeled
oligonucleotide was preincubated with the a-TTF-1 antibody
alone, but this failed to produce the supershifted band (lane
12). Furthermore, the incubation with a preimmune serum
did not induce a supershift in control nuclear extracts (lanes
14 and 15). From these results, we conclude that the variation
observed on TTF-1 mRNA levels in all the experimental
approaches studied in this work parallels the variation found
in TTF-1 protein levels and in its binding activity.
Nitrofen decreases TTF-1 gene promoter activity
To elucidate the molecular mechanism that induces down-
regulation of TTF-1 gene expression in our animal lung hy-
poplasia model, we used the H441 pulmonary cell line. This
cell line is used extensively in studies of lung-specific gene
expression (4, 29–31, 34), and we have shown that, in these
cells (as well as in rat fetal lung), NF reduces TTF-1 mRNA
levels in a dose- and time-dependent manner, with maximal
inhibition using 1.5 mm NF after 72 h of treatment (43). The
doses studied were calculated in accordance with pharma-
cokinetic and biotransformation data previously described
for NF (25, 44). The dose used corresponded to the cellular
absorption of NF found in the embryonic compartment (25,
44). To determine whether the down-regulation of TTF-1
gene expression described in this work correlates with a
decrease in TTF-1 promoter activity, and whether Dex re-
verses this effect, a construct spanning 2.8 kb of the human
TTF-1 59-flanking region (34), linked to a luciferase reporter
gene (Fig. 6A), was transiently transfected into H441 cells. In
all transfections, the reporter vector pSV0AL-A5 (34) was
transfected in parallel as control. After transfection, cells
were maintained in medium containing only 0.2% FBS, with
or without 1.5 mm NF, for the following 48 h. The low serum
was used to detect the Dex effect more clearly; as in 10%
serum, the hormone effect is masked by the endogenous
glucocorticoid content of serum (45). The cells were then
treated, or not, for another 24 h with 100 nm Dex. Nitrofen
decreased TTF-1 promoter activity approximately 3-fold, rel-
ative to control cells (Fig. 6B). Dex treatment increased the
promoter activity in NF-treated cells but not in control cells.
In light of the results obtained, we questioned whether the
NF action on TTF-1 occurs by interference of this compound
with the TTF-1 synthesis mechanism or by direct interference
with its transcriptional activity. To approach this question,
H441 cells were cotransfected with a 2.8-kb fragment of the
human TTF-1 promoter and an expression vector for the
TTF-1 complementary DNA (cDNA) (38). Overexpression of
TTF-1 increased TTF-1 promoter activity 2-fold (Fig. 6C),
because of the existence of multiple TTF-1-binding sites in
this promoter (Fig. 6A) (34). The down-regulation of TTF-1
elicited by NF, as well as the reestablishment of activity
induced by Dex, also occurred when the exogenous tran-
FIG. 4. TTF-1/DNA binding in rat fetal lungs after different treat-
ments. Nuclear extracts from control (lane 2) or NF groups (lane 8)
[untreated or treated with Dex (lanes 5 and 9), TRH (lanes 6 and 10),
or both hormones together (lanes 7 and 11)] were incubated with a
radiolabeled synthetic oligonucleotide (SPB-f1) derived from the TTF-
1-binding-site of the SP-B promoter. Free and bound DNA were re-
solved in a gel shift assay. For competition, a 100-fold excess of
unlabeled related SPB-f1 oligonucleotide (lane 3) or an unrelated
oligonucleotide (lane 4) was used.
FIG. 5. TTF-1 supershift assay in control or hypoplastic fetal lungs,
untreated or treated with Dex. Gel shift assay was performed as
described in Fig. 4 [using nuclear extracts from control (lane 2), NF
(lane 7), or NF plus Dex (NF 1 Dex) (lane 9) groups]. The specificity
of the retarded complex was established by competition with a 100-
fold excess of a related (lanes 3, 7, and 10) or unrelated (lane 4)
oligonucleotide and by supershift with an anti-TTF-1-specific anti-
body (lanes 5, 8, and 11). The preimmune serum (lane 15) and the
antibody alone, without nuclear extracts (lane 12), were used as
control of supershift specificity.
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scription factor was cotransfected (Fig. 6C). These data sug-
gest that NF may act through a mechanism that impairs the
transcriptional activity of TTF-1 and that the glucocorticoids
would counteract this mechanism.
Discussion
Hypoplastic lungs of infants with congenital diaphrag-
matic hernia seem to be delayed in their advancement
through developmental stages. One consequence of this de-
velopmental delay is that the hypoplastic lungs have fewer
bronchial branches and a delay in epithelial cell differenti-
ation, with a clear SP deficiency. Teratogens, administered to
pregnant rats on the appropriate gestational days, disturb
organogenesis during early embryonic life and induce mal-
formations that provide good models for several human
disorders. Nitrofen-exposed rat fetuses have lung hypopla-
sia with biochemical immaturity. This fetal rat model is,
therefore, the most appropriate for our study, because it
reproduces the same lung morphological changes described
in human (22–24).
Using the above model, we demonstrate that the home-
odomain transcription factor TTF-1 has an essential role in
the pathogenesis of lung hypoplasia (16, 29). This role has
been also demonstrated in mice lacking TTF-1 expression.
Mutant Hoxa-5 mice (46) also have defects in lung ontogeny
caused by reduction of TTF-1 expression, inducing a signif-
icant decrease in SP proteins that cause respiratory dysfunc-
tion similar to the respiratory distress syndrome described in
premature human infants. Our results show that hypoplastic
lungs have severely decreased TTF-1, mRNA, and protein
levels and a consequential reduction in TTF-1-binding ac-
tivity to the proximal SP-B promoter. Moreover, the up-
stream DNA of the rat and human TTF-1 gene possesses
many putative TTF-1-binding sites (34, 47), suggesting that
TTF-1 gene may be autoregulated (34). In consequence, a
reduction in TTF-1 binding to its own promoter should have
an effect at the transcriptional level. We have shown that NF,
the herbicide that induces lung hypoplasia in rats, down-
regulates the 2.8-kb fragment of the TTF-1 promoter activity,
which includes the putative TTF-1-binding sites. In conse-
quence, less transcription factor is synthesized. These results
support the possible autoregulation of TTF-1, confirming
that TTF-1 is a transcription factor essential in lung forma-
tion, and that its low expression is essential in the patho-
genesis of lung hypoplasia.
Prenatal glucocorticoid therapy accelerates pulmonary de-
velopment in premature infants (26, 27), and the addition of
prenatal TRH therapy is no more beneficial than the use of
glucocorticoids alone (28). Our results show that glucocor-
ticoid treatment induces expression of TTF-1 mRNA and
TTF-1 protein and, in consequence, induces an increase in
TTF-1-binding activity to the SP-B proximal promoter, only
in hypoplastic lungs. This increase is reproduced in TTF-1
promoter activity, although only in NF-treated cells. Glu-
cocorticoids may thus restore TTF-1 and SP-B levels by in-
creasing the TTF-1 autoregulatory mechanism. As a conse-
quence, there is an increase in the TTF-1 protein level, which
may then bind at a high ratio to its target promoter genes. We
also have shown that treatment with TRH alone, or combined
with Dex, had minimal consequences, as compared with the
Dex effect in hypoplastic fetal lungs. These results are in
agreement with a previous work that has shown that pre-
natal corticoid therapy improves pulmonary morphology in
NF-treated rats, whereas TRH had minimal beneficial effects
(48). Results also are in accordance with data on prevention
of lung disease in human preterm infants (26).
Because NF induces a delay in lung development, the
morphology of lungs from NF-treated fetuses is different
from that of control, having proportionately more mesen-
chimal than epithelial cells (49). We believe that the effect of
NF in fetal lung takes place mainly in epithelial cells affecting
directly lung-specific genes expression. This idea is rein-
forced by the fact that the same results obtained in rats were
FIG. 6. Regulation of TTF-1 promoter activity by NF and Dex. A,
Schematic diagram of the 2.8-kb human TTF-1 promoter linked to the
luciferase (LUC) reporter gene. The arrows represent the TTF-1-
binding sites. The TTF-1 promoter activity was obtained either after
transfection of the above construct to H441 cells (B) or by cotrans-
fection with the expression vectors RC-CMV with no insert or har-
boring the cDNA for TTF-1 (CMV-THA). Transfected cells were main-
tained for 48 h in 0.2% serum, plus or minus NF, then incubated alone
or with Dex for another 24 h. Luciferase activity was determined as
relative light units normalizing to CAT activity derived from the
RSV-CAT transfected to adjustments of transfection efficiency. The
data are mean 6 SEM of three independent experiments. Significant
differences among groups are indicated, and means: *, P , 0.01 (one
group vs. control group); , P , 0.01 (one group vs. CMV-THA group);
ø, P , 0.01 (one group vs. NF group).
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found in epithelial culture of H441 cells. The intrinsic mo-
lecular mechanism of NF and glucocorticoids on TTF-1 gene
expression is unknown. TTF-1 regulation has been exten-
sively studied in FRTL-5 cells, showing down-regulation by
TSH via cAMP (13, 50). To our knowledge, however, there
is no evidence that NF increases cAMP in lung cells. Inter-
estingly, clear down-regulation of TTF-1-binding activity is
induced by an oxidative state (51), and reduction/oxidation
(redox) reactions are intimately involved in the control of
biological processes, including modulation of transcription
factor function, e.g. AP-1 and NF-kB (52, 53). Antioxidant
compounds are also described to reverse fetal rat lung hy-
poplasia (54), and Dex increases antioxidant enzymes (55). In
addition, no functional glucocorticoid response elements
have been reported in the promoter region of TTF-1. It thus
seems that glucocorticoid response element-mediated gene
induction is not the basis of this regulation. Based on these
observations, we hypothesized that a possible mechanism for
down-regulation of TTF-1 by NF and its restoration by glu-
cocorticoids may be elicited by redox mechanisms. This idea
is supported by the fact that cellular glucocorticoid respon-
siveness is coordinately modulated by the redox state and
thioredoxin levels (56). This plausible mechanism remains to
be studied; however, our data, showing that activity of ex-
ogenous TTF-1 cotransfected to H441 cells is also regulated
by both NF and glucocorticoids, reinforce this hypothesis.
In conclusion, the data reported in this study demonstrate
that lung hypoplasia is induced, at least in part, by an al-
teration of one of the main transcription factors involved in
lung organogenesis. This work also supports routine in utero
glucocorticoid treatment for patients expected to have lung
hypoplasia.
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